



SDI Review Form 1.6

Journal Name:	<u>British Journal of Medicine and Medical Research</u>
Manuscript Number:	2014_BJMMR_13820
Title of the Manuscript:	Dose-dependent Modulation of Lipid Parameters and Inflammatory Biomarkers by δ-Tocotrienol in Hypercholesterolemic Subjects
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<p>1- Abstract: please differentiate between miRNA and mRNA [please mention this difference in mat & methods] micro ribonuclear acids and messenger RNA????????????????</p> <p>The present study is a dose-response study examined the effects of δ-tocotrienol free from tocopherols on serum lipid parameters and several inflammatory biomarkers (TNF-α, IL-4, IL-6, IL-8) including circulating miRNAs expression in hypercholesterolemic subjects for 30-weeks</p> <p>However, the conclusion The present results confirm that consumption of <u>δ-tocotrienol plus AHA</u> Step-1 diet causes significant therapeutic effects → Title include only <u>δ-tocotrienol→ the authors should change the title to “ a combination bet. δ-tocotrienol and AHA step 1 diet” to be more representable to the results of the study.</u></p> <p>2- Introduction is good with a clear research question at its end</p> <p>3- At line 113: give a title of a paragraph materials: as the authors mentioned some of their materials and their source. Then at the same paragraph, they should mention the</p>	<p>Abstract has been modified. MicroRNA (miRNA) and messenger ribonucleic acid (mRNA) have been spelled out throughout the manuscript.</p> <p>Title has been modified. AHA Step-1 diet has added in the title. Dose-response is of δ-tocotrienol and not of AHA Step-1 diet.</p>



SDI Review Form 1.6

	<p>commercial kits [name, company, country] of all the measured parameters in the study.</p> <p><u>Line 114: please mention your reference of serum total cholesterol level > 5.50 mmol/L that means = a hypercholesterol. Patient.</u></p> <p>Mention type of consent: oral or written</p> <p>At line 124: they mentioned exclusion criteria with no obvious inclusion criteria. I preferred under study design to place 2 titles: inclusion criteria (1,2,3.....) then exclusion criteria (1,2,3,.....) then causes of termination of study: death- severe illness- hospitalization etc...</p> <p>I think that these 3 subtitles are very important for any clinical trial.</p> <p>Sample size: please justify the number of 30 patients- your randomization method- the computer program used , if any, its version, company and country</p> <p>In figure 2 , in title of the study, in methodology : the authors must place AHA step 1 diet + <u>δ-tocotrienol to avoid any confusion [I went up and down to understand the presence of this combination]</u></p> <p><u>Results are well explained and self explanatory.</u></p> <p><u>Discussion is good and explains results in relation to other studies in a good manner</u></p> <p><u>Up-to-date and relevant references</u></p>	<p>Manuscript has been modified according to reviewer's suggestion, including all the suggested changes.</p> <p>References have been updated</p>
--	---	--



SDI Review Form 1.6

<u>Minor</u> REVISION comments		
<u>Optional/General</u> comments	. A good research question with a well-done laboratory work. But we need justification of sample size and the method of randomization	